Payment overview · 2025
General Payments
$694.50
30 reported records · 11 companies
Healthcare provider profile · identity verified
Joseph Frank Roberts, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GRENADA, MS · NPI 1023129608
Verified facts
What the public records show
CMS Open Payments records show Joseph Frank Roberts, M.D. received $694.50 in general payments during 2025 across 30 reported records.
ABBVIE INC. accounted for 37.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 433 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $262.11 | 37.7% | 16 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $142.88 | 20.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $71.00 | 10.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.44 | 5.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $36.81 | 5.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $32.17 | 4.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.31 | 3.8% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $24.77 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.05 | 3.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.69 | 2.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.27 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $694.50 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $158.75 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $158.75 | 11 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $142.88 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.29 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.44 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $36.81 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $34.17 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $32.17 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $28.07 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $28.07 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $28.07 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 433 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 155 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 140 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
162 | 37 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
93 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
140 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
433 | 56 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1151 | 157 |
| Gabapentin | Gabapentin | 1138 | 247 |
| Amlodipine Besylate | Amlodipine Besylate | 1130 | 240 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1102 | 221 |
| Furosemide | Furosemide | 1047 | 220 |
| Losartan Potassium | Losartan Potassium | 1000 | 210 |
| Levothyroxine Sodium | Levothyroxine Sodium | 873 | 173 |
| Potassium Chloride | Potassium Chloride | 791 | 154 |
| Atorvastatin Calcium | Atorvastatin Calcium | 723 | 141 |
| Clopidogrel | Clopidogrel Bisulfate | 644 | 120 |
| Montelukast Sodium | Montelukast Sodium | 629 | 174 |
| Omeprazole | Omeprazole | 581 | 128 |
| Metformin Hcl | Metformin Hcl | 500 | 114 |
| Meloxicam | Meloxicam | 499 | 131 |
| Famotidine | Famotidine | 475 | 129 |
| Sertraline Hcl | Sertraline Hcl | 440 | 59 |
| Eliquis | Apixaban | 433 | 56 |
| Carvedilol | Carvedilol | 398 | 80 |
| Quetiapine Fumarate | Quetiapine Fumarate | 386 | 38 |
| Alprazolam | Alprazolam | 370 | 69 |
| Donepezil Hcl | Donepezil Hcl | 367 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 365 | 60 |
| Prednisone | Prednisone | 354 | 230 |
| Metoprolol Succinate | Metoprolol Succinate | 340 | 81 |
| Mirtazapine | Mirtazapine | 332 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 331 | 88 |
| Glimepiride | Glimepiride | 317 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 309 | 70 |
| Buspirone Hcl | Buspirone Hcl | 300 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 295 | 59 |
| Hydralazine Hcl | Hydralazine Hcl | 284 | 57 |
| Clonidine Hcl | Clonidine Hcl | 279 | 86 |
| Tramadol Hcl | Tramadol Hcl | 278 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 276 | 55 |
| Lisinopril | Lisinopril | 272 | 50 |
| Trazodone Hcl | Trazodone Hcl | 271 | 62 |
| Diclofenac Sodium | Diclofenac Sodium | 266 | 74 |
| Memantine Hcl | Memantine Hcl | 263 | 37 |
| Allopurinol | Allopurinol | 248 | 55 |
| Temazepam | Temazepam | 240 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 229 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 228 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 223 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 220 | 43 |
| Pregabalin | Pregabalin | 212 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 200 | 73 |
| Tizanidine Hcl | Tizanidine Hcl | 196 | 29 |
| Clonazepam | Clonazepam | 194 | 32 |
| Atenolol | Atenolol | 188 | 36 |
| Spironolactone | Spironolactone | 179 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 177 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 174 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 173 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 171 | 45 |
| Amiodarone Hcl | Amiodarone Hcl | 169 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 169 | 76 |
| Levetiracetam | Levetiracetam | 165 | 23 |
| Linzess | Linaclotide | 162 | 37 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 157 | 32 |
| Azithromycin | Azithromycin | 156 | 133 |
| Celecoxib | Celecoxib | 155 | 35 |
| Jardiance | Empagliflozin | 155 | 15 |
| Tradjenta | Linagliptin | 154 | suppressed |
| Ibuprofen | Ibuprofen | 152 | 43 |
| Meclizine Hcl | Meclizine Hcl | 151 | 43 |
| Lovastatin | Lovastatin | 146 | 35 |
| Divalproex Sodium | Divalproex Sodium | 140 | 16 |
| Ozempic | Semaglutide | 140 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 138 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 137 | 39 |
| Cephalexin | Cephalexin | 133 | 92 |
| Oxybutynin Chloride | Oxybutynin Chloride | 133 | 20 |
| Mupirocin | Mupirocin | 132 | 53 |
| Aripiprazole | Aripiprazole | 128 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 128 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 124 | 18 |
| Simvastatin | Simvastatin | 123 | 33 |
| Metformin Hcl Er | Metformin Hcl | 122 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 121 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 119 | 29 |
| Fluconazole | Fluconazole | 118 | 64 |
| Tresiba Flextouch U-200 | Insulin Degludec | 118 | 15 |
| Nifedipine Er | Nifedipine | 115 | 18 |
| Januvia | Sitagliptin Phosphate | 113 | 15 |
| Baclofen | Baclofen | 110 | 15 |
| Risperidone | Risperidone | 104 | 14 |
| Xarelto | Rivaroxaban | 101 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 100 | 23 |
| Bupropion Xl | Bupropion Hcl | 98 | 20 |
| Tresiba Flextouch U-100 | Insulin Degludec | 93 | 17 |
| Trulicity | Dulaglutide | 93 | 12 |
| Ezetimibe | Ezetimibe | 91 | 23 |
| Warfarin Sodium | Warfarin Sodium | 87 | 21 |
| Estradiol | Estradiol | 86 | 26 |
| Finasteride | Finasteride | 86 | 15 |
| Entresto | Sacubitril/Valsartan | 83 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 82 | 29 |
| Mounjaro | Tirzepatide | 82 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 80 | 15 |
| Myrbetriq | Mirabegron | 79 | suppressed |
| Irbesartan | Irbesartan | 78 | 22 |
| Colchicine | Colchicine | 77 | 23 |
| Lorazepam | Lorazepam | 77 | 21 |
| Methocarbamol | Methocarbamol | 77 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 76 | 17 |
| Nitroglycerin | Nitroglycerin | 75 | 39 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 74 | 16 |
| Sucralfate | Sucralfate | 74 | 14 |
| Cefuroxime | Cefuroxime Axetil | 70 | 58 |
| Metoclopramide Hcl | Metoclopramide Hcl | 67 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 66 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 64 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 64 | suppressed |
| Novolog Flexpen | Insulin Aspart | 64 | 20 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 64 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 63 | suppressed |
| Synthroid | Levothyroxine Sodium | 63 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | 11 |
| Levofloxacin | Levofloxacin | 62 | 54 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 17 |
| Torsemide | Torsemide | 62 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 61 | 46 |
| Amoxicillin | Amoxicillin | 60 | 48 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 60 | suppressed |
| Ondansetron Odt | Ondansetron | 58 | 22 |
| Promethazine Hcl | Promethazine Hcl | 58 | 23 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 56 | suppressed |
| Novolog | Insulin Aspart | 56 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 35 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 54 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 11 |
| Propranolol Hcl | Propranolol Hcl | 53 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 52 | suppressed |
| Diazepam | Diazepam | 51 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 23 |
| Lactulose | Lactulose | 51 | suppressed |
| Glipizide | Glipizide | 50 | 18 |
| Labetalol Hcl | Labetalol Hcl | 49 | suppressed |
| Rybelsus | Semaglutide | 49 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 48 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 48 | 13 |
| Chlorthalidone | Chlorthalidone | 47 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Acyclovir | Acyclovir | 46 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 46 | 15 |
| Nystatin | Nystatin | 46 | 26 |
| Valsartan | Valsartan | 45 | 14 |
| Brilinta | Ticagrelor | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 37 |
| Gemtesa | Vibegron | 43 | suppressed |
| Carisoprodol | Carisoprodol | 42 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 42 | suppressed |
| Lamotrigine | Lamotrigine | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 42 | suppressed |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 40 | 23 |
| Febuxostat | Febuxostat | 40 | 12 |
| Creon | Lipase/Protease/Amylase | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 29 |
| Bumetanide | Bumetanide | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | suppressed |
| Latanoprost | Latanoprost | 37 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Clonidine | Clonidine | 35 | suppressed |
| Ketoconazole | Ketoconazole | 35 | 15 |
| Olanzapine | Olanzapine | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 28 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 34 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 32 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 32 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 30 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 30 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 29 | 21 |
| Lumigan | Bimatoprost | 29 | suppressed |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Metronidazole | Metronidazole | 29 | 21 |
| Rivastigmine | Rivastigmine Tartrate | 29 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 28 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 28 | 20 |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Pentoxifylline | Pentoxifylline | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Ubrelvy | Ubrogepant | 27 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 25 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 24 | 18 |
| Novolin R | Insulin Regular, Human | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 11 |
| Fiasp | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 22 | suppressed |
| Verapamil Sr | Verapamil Hcl | 22 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Tresiba | Insulin Degludec | 19 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Misoprostol | Misoprostol | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Glucagon Emergency Kit | Glucagon | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Klor-Con | Potassium Chloride | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cymbalta | Duloxetine Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Linezolid | Linezolid | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $694.50 · 30 records | ABBVIE INC. | AIRSUPRA, AVYCAZ, CAPLYTA, DALVANCE, ELIQUIS, Hillrom - Vest System Model 105 Home Care, IBSRELA, INSPIRE, JARDIANCE, KISUNLA, Korlym, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, TEFLARO, UBRELVY, VRAYLAR, ZEPBOUND, Zunveyl | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error